Physician profile
Leah Gallagher
NPI 1093060345
$4,658.53
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,599 · 2022: $1,009 · 2023: $33.21 · 2024: $17.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $50.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $50.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $907.18 | 2021-2022 | |
| Abbvie INC. | $514.98 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $405.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $269.48 | 2021-2024 | Breztri |
| Astellas Pharma US INC | $236.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $180.13 | 2021-2022 | |
| Amarin Pharma, INC. | $158.62 | 2021 | |
| Optinose US, INC. | $150.20 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.98 | 2021-2022 | |
| Amgen INC. | $121.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $112.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $110.19 | 2021-2022 | |
| Pfizer INC. | $88.26 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.92 | 2021-2022 | |
| Esperion Therapeutics, INC. | $68.96 | 2021-2022 | |
| Lundbeck LLC | $66.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $55.29 | 2021 | |
| Ironwood Pharmaceuticals, INC | $48.04 | 2021-2022 | |
| Ucb, INC. | $48.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $41.21 | 2021 | |
| Scilex Pharmaceuticals INC. | $29.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.03 | 2021 | |
| Biogen, INC. | $17.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.50 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.